Activities
- 1 - 50 out of 84 results
Search results
-
Lower Risk of Venous Thromboembolism with Body-identical Estrogens in Contraception: Evidence from Multiple Levels
Douxfils, J. (Speaker)
5 Mar 2026Activity: Talk or presentation types › Invited talk
-
Current overview of the cardiovascular risk of estetrol-drospirenone versus ethinylestradiol containing pills
Douxfils, J. (Speaker)
7 Mar 2026Activity: Talk or presentation types › Invited talk
-
Understanding the value of natural estrogens From global consensus to clinical application with E4/DRSP
Douxfils, J. (Speaker)
6 Mar 2026Activity: Talk or presentation types › Invited talk
-
Advancing combined hormonal contraception: the scientific and clinical rationale for natural estrogens
Douxfils, J. (Speaker)
5 Mar 2026Activity: Talk or presentation types › Invited talk
-
Effect of Estetrol on Acquired Activated Protein C Resistance in Postmenopausal Women: A Phase 3 Randomized Trial
Douxfils, J. (Speaker)
6 Mar 2026Activity: Talk or presentation types › Oral presentation
-
Novedades en anticoncepción hormonal oral (AHO): Estetrol, primer estrógeno selectivo (NEST) ¿Estamos ante un cambio de paradigma en AHO?Pensando en seguridad: actualización en farmacovigilancia
Douxfils, J. (Speaker)
27 Feb 2026Activity: Talk or presentation types › Invited talk
-
Pourquoi l’estétrol allie sécurité contraceptive et sécurité cardiovasculaire ? Un shift dans la prise en charge de la contraception
Douxfils, J. (Speaker)
25 Feb 2026Activity: Talk or presentation types › Invited talk
-
Endométriose: Risque vasculaire des traitements médicaux
Douxfils, J. (Speaker)
2 Oct 2025Activity: Talk or presentation types › Invited talk
-
Effect of Estetrol on Acquired Activated Protein C Resistance in Postmenopausal Women: A Phase 3 Randomized Study
Douxfils, J. (Speaker)
23 Oct 2025Activity: Talk or presentation types › Invited talk
-
Risque de thrombose associé aux thérapies hormonales : de l’évaluation à la prévention
Douxfils, J. (Speaker)
15 Oct 2025Activity: Talk or presentation types › Invited talk
-
A Phase 3 Trial of Estetrol in Postmenopausal Women with Moderate to Severe Vasomotor Symptoms Shows No Effect on Blood Pressure, Including in Women with Cardiovascular Risk Factors
Douxfils, J. (Speaker)
23 Oct 2025Activity: Talk or presentation types › Invited talk
-
Modern Innovations in Combined Hormonal Contraceptives: Clinical Implications and Global Access
Douxfils, J. (Speaker)
7 Oct 2025Activity: Talk or presentation types › Invited talk
-
Le tournant des œstrogènes : pourquoi l’estétrol allie efficacité contraceptive et sécurité cardiovasculaire
Douxfils, J. (Speaker)
4 Sept 2025Activity: Talk or presentation types › Oral presentation
-
Risque thrombotique des oestroprogestatifs
Douxfils, J. (Speaker)
3 Apr 2025Activity: Talk or presentation types › Invited talk
-
Lower reporting of venous thromboembolisms events with natural estrogen-based COCs compared to ethinylestradiol containing pills: A disproportionality analysis of the Eudravigilance database.
Douxfils, J. (Speaker)
22 Mar 2025Activity: Talk or presentation types › Invited talk
-
Risque thromboembolique veineux de l’add back thérapie
Douxfils, J. (Speaker)
13 Mar 2025Activity: Talk or presentation types › Invited talk
-
Does E4/DRSP have minimal impact on hemostasis and VTE risk? The evidence is growing
Douxfils, J. (Speaker)
20 Mar 2025Activity: Talk or presentation types › Invited talk
-
Risque thrombotique des oestroprogestatifs : quoi de neuf ?
Douxfils, J. (Speaker)
13 Mar 2025Activity: Talk or presentation types › Invited talk
-
Effect of E4/DRSP 15/3 mg on Hemostasis Parameters in Post-Menarchal Adolescents: A Phase 3 Multicentre Study
Douxfils, J. (Speaker)
20 Mar 2025Activity: Talk or presentation types › Oral presentation
-
Towards safer and more responsible use of estrogen-based oral contraceptives
Douxfils, J. (Speaker)
22 Mar 2025Activity: Talk or presentation types › Invited talk
-
Vers une utilisation plus sûre et responsable des contraceptifs oraux à base d'estrogène
Douxfils, J. (Speaker)
11 Feb 2025Activity: Talk or presentation types › Invited talk
-
The normalized Activated Protein C sensitivity ratio (nAPCsr): the INR of the gynecologist for a safer prescription of estrogen-containing products
Douxfils, J. (Speaker)
11 Dec 2024Activity: Talk or presentation types › Invited talk
-
31ST BTSH
Didembourg, M. (Contributor) & Gillot, C. (Contributor)
28 Nov 2024 → 29 Nov 2024Activity: Participating in or organising an event types › Participation in conference
-
Thromboses associées aux contraceptifs hormonaux combinés: évaluation du risque et suivi thérapeutique par un nouveau test, le nAPCr
Douxfils, J. (Speaker)
27 Jun 2024Activity: Talk or presentation types › Invited talk
-
Estetrol - an estrogen through life: Cardiovascular impact and the risk of VTE
Douxfils, J. (Speaker)
4 Jun 2024Activity: Talk or presentation types › Invited talk
-
Risque de thrombose associés aux contraceptifs hormonaux combinés - pourquoi l’évaluation de la résistance à la protéine C activée, appelée nAPCsr, est-elle importante?
Douxfils, J. (Speaker)
20 Jun 2024Activity: Talk or presentation types › Invited talk
-
Is there a physiological explanation to VTE risk observed in epidemiological studies?
Douxfils, J. (Speaker)
1 May 2024Activity: Talk or presentation types › Invited talk
-
Is there new data to support the screening of women for hereditary thrombophilia before prescribing pills?
Douxfils, J. (Speaker)
1 May 2024Activity: Talk or presentation types › Invited talk
-
International Society of Gynecological Endocrinology: the 21st world congress
Didembourg, M. (Contributor) & Donis, N. (Contributor)
8 May 2024 → 11 May 2024Activity: Participating in or organising an event types › Participation in conference
-
Thromboses associées aux contraceptifs hormonaux combinés: évaluation du risque et suivi thérapeutique par un nouveau test, le nAPCr
Douxfils, J. (Speaker)
18 Apr 2024Activity: Talk or presentation types › Invited talk
-
Impact de l'estetrol sur la coagulation chez les femmes ménopausées
Didembourg, M. (Speaker)
28 Mar 2024Activity: Talk or presentation types › Oral presentation
-
Risque de thrombose associés aux contraceptifs hormonaux combinés - pourquoi l’évaluation de la résistance à la protéine C activée, appelée nAPCsr, est-elle importante?
Douxfils, J. (Speaker)
16 Mar 2024Activity: Talk or presentation types › Invited talk
-
Cardiovascular safety: the point of view of the veins
Douxfils, J. (Speaker)
8 Mar 2024Activity: Talk or presentation types › Invited talk
-
Risque de thrombose associés aux contraceptifs hormonaux combinés - pourquoi l’évaluation de la résistance à la protéine C activée, appelée nAPCsr, est-elle importante?
Douxfils, J. (Speaker)
22 Feb 2024Activity: Talk or presentation types › Invited talk
-
Hormones-induced Coagulopathies — Evaluation of the Prothrombotic State Using a Global Coagulation Assay
Douxfils, J. (Speaker)
25 Jan 2024Activity: Talk or presentation types › Invited talk
-
Impact of progestagen alone or associated with estrogen on the coagulation: A state of the art in 2023
Douxfils, J. (Speaker)
1 Dec 2023Activity: Talk or presentation types › Invited talk
-
30th Annual Meeting of the Belgian Society on Thrombosis and Haemostasis (BSTH)
Gillot, C. (Poster), Didembourg, M. (Poster), Vassart, J. (Participant) & Vassart, J. (Poster)
30 Nov 2023 → 1 Dec 2023Activity: Participating in or organising an event types › Participation in conference
-
Prediction of venous thromboembolism risk associated with combined oral contraceptives: an exploratory model
Morimont, L. (Speaker) & Douxfils, J. (Speaker)
30 Nov 2023Activity: Talk or presentation types › Oral presentation
-
Hemostasis parameters with estetrol/drospirenone - why APC resistance matters
Douxfils, J. (Speaker)
30 Nov 2023Activity: Talk or presentation types › Invited talk
-
Combined Hormonal Contraceptives - Induced Coagulopathies Evaluation of the Prothrombotic State Using a Global Coagulation Assay
Douxfils, J. (Speaker) & Morimont, L. (Speaker)
4 Oct 2023Activity: Talk or presentation types › Invited talk
-
FIGO - XXIVe World Congress of Gynecology and Obstetrics
Douxfils, J. (Speaker)
9 Oct 2023 → 13 Oct 2023Activity: Participating in or organising an event types › Participation in conference
-
Safety profile of E4: Recent advance and evidence
Douxfils, J. (Keynote speaker)
18 Sept 2023Activity: Talk or presentation types › Invited talk
-
Donesta Partner Meeting : Acquired APC resistance as a marker for VTE, how does the estrogens differ?
Douxfils, J. (Keynote speaker)
4 Sept 2023 → 8 Sept 2023Activity: Talk or presentation types › Invited talk
-
Aquired APC-resistance as a marker for VTE, how reliable?
Douxfils, J. (Invited speaker)
27 Aug 2023Activity: Talk or presentation types › Invited talk
-
Évaluation du risque vasculaire des contraceptifs
Douxfils, J. (Invited speaker)
21 Jun 2023 → 23 Jun 2023Activity: Talk or presentation types › Invited talk
-
Risque induit par les oestrogènes de synthèse en clinique
Douxfils, J. (Invited speaker)
8 Jun 2023Activity: Talk or presentation types › Invited talk
-
ISTH 2023 Congress
Didembourg, M. (Poster) & Morimont, L. (Contributor)
24 Jun 2023 → 28 Jun 2023Activity: Participating in or organising an event types › Participation in conference
-
Fantastic 4 - E4stetrol in Women's Health
Douxfils, J. (Invited speaker) & Foidart, J.-M. (Invited speaker)
4 May 2023 → 6 May 2023Activity: Talk or presentation types › Oral presentation
-
28th EBCOG congress
Morimont, L. (Contributor)
18 May 2023 → 20 May 2023Activity: Participating in or organising an event types › Participation in conference
-
Prediction Of Venous Thromboembolism Risk Associated With Combined Oral Contraceptives: An Exploratory Model
Morimont, L. (Speaker)
19 May 2023Activity: Talk or presentation types › Oral presentation